As filed with the Securities and Exchange Commission
on June 5, 2024
Registration No. 333-
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
BEIGENE, LTD.
(Exact name of registrant as specified in its charter)
Cayman Islands
(State or other jurisdiction of
incorporation or organization) |
|
98-1209416
(I.R.S. Employer
Identification Number) |
c/o Mourant Governance Services (Cayman) Limited
94 Solaris Avenue, Camana Bay
Grand Cayman KY1-1108
Cayman Islands
(Address, including zip code, of Principal Executive
Offices)
Third Amended and Restated 2016 Share Option
and Incentive Plan
Fourth
Amended and Restated 2018 Employee Share Purchase Plan
(Full title of the plan)
Cogency Global Inc.
122 East 42nd Street, 18th
Floor
New
York, New York 10168
(Name and address of agent for service)
(800) 221-0102
(Telephone number, including area code, of agent
for service)
Copy to:
Chan Lee
Senior Vice President, General Counsel
c/o BeiGene USA, Inc.
55 Cambridge Parkway
Suite 700W
Cambridge, MA 02142
(781) 801-1800
Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions
of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging
growth company” in Rule 12b-2 of the Exchange Act.
Large
accelerated filer x
Non-accelerated
filer ¨
|
|
|
|
|
Accelerated
filer o
Smaller
reporting company o
Emerging
growth company o |
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act. o
REGISTRATION OF ADDITIONAL SECURITIES PURSUANT
TO GENERAL INSTRUCTION E
This Registration Statement
on Form S-8 registers an additional 92,820,000 ordinary shares under BeiGene, Ltd.’s (the “Registrant”) Third
Amended and Restated 2016 Share Option and Incentive Plan (the “2016 Equity Plan”), approved by the Registrant’s shareholders
on June 5, 2024, representing an increase of 92,820,000 ordinary shares to the number of shares authorized under the Registrant’s
Second Amended and Restated 2016 Share Option and Incentive Plan. The additional shares are of the same class as other securities relating
to the 2016 Equity Plan for which the Registrant’s Registration Statements on Form S-8 (Registration Nos. 333-209410, 333-216885,
333-223319, 333-228786, 333-241697 and 333-266639) filed on February 5, 2016; March 22, 2017; February 28, 2018; December 13, 2018; August 6, 2020; and August 8, 2022, respectively, are effective. The information contained in those registration statements
is hereby incorporated by reference pursuant to General Instruction E.
This Registration Statement
on Form S-8 registers an additional 5,070,000 ordinary shares under the Registrant’s Fourth Amended and Restated 2018 Employee
Share Purchase Plan (the “2018 ESPP”), approved by the Registrant’s shareholders on June 5, 2024, representing
an increase of 5,070,000 ordinary shares to the number of shares authorized under the Registrant’s Third Amended and Restated 2018
Employee Share Purchase Plan. The additional shares are of the same class as other securities relating to the 2018 ESPP for which the
Registrant’s Registration Statements on Form S-8 (Registration Nos. 333-225543 and 333-228786) filed on June 8, 2018 and
December 13, 2018, respectively, are effective. The information contained in the registration statement is hereby incorporated by
reference pursuant to General Instruction E.
PART II
INFORMATION REQUIRED
IN THE REGISTRATION STATEMENT
See the Exhibit Index below for a list
of exhibits filed as a part of, or incorporated by reference into, this Registration Statement, which Exhibit Index is incorporated
herein by reference.
Exhibit No. |
|
Exhibit Description |
Filed/ Furnished Herewith |
Incorporated by Reference Herein from Form or Schedule |
Filing Date |
SEC File/ Reg. Number |
4.1 |
|
Seventh Amended and Restated Memorandum and Articles of Association of the Registrant, as currently in effect |
|
8-K (Exhibit 3.1) |
6/15/2023 |
001-37686 |
|
|
|
|
|
|
|
4.2 |
.1 |
Deposit Agreement dated February 5, 2016 by and among the Registrant, the Depositary and holders of the American Depositary Receipts |
|
8-K (Exhibit 4.1) |
2/11/2016 |
001-37686 |
|
|
|
|
|
|
|
|
.2 |
Amendment No. 1 to Deposit Agreement, dated April 11, 2016, by and among the Registrant, Citibank, N.A. and holders of the American Depositary Receipts |
|
8-K (Exhibit 4.1) |
4/11/2016 |
001-37686 |
|
|
|
|
|
|
|
|
.3 |
Letter Agreement, dated as of July 11, 2016, between the Registrant and Citibank, N.A. |
|
10-Q (Exhibit 4.7) |
8/10/2016 |
001-37686 |
|
|
|
|
|
|
|
|
.4 |
Form of Letter Agreement between the Registrant and Citibank, N.A. |
|
10-Q (Exhibit 4.9) |
5/10/2017 |
001-37686 |
|
|
|
|
|
|
|
4.3 |
|
Specimen Certificate for Ordinary Shares |
|
S-1 (Exhibit 4.3) |
12/9/2015 |
333-207459 |
|
|
|
|
|
|
|
4.4 |
|
Form of American Depositary Receipt (included in Exhibit 4.2.1 |
|
|
|
|
|
|
|
|
|
|
|
4.5 |
.1 |
Registration Rights Agreement, dated as of November 16, 2016, by and among the Registrant and the investors named therein |
|
8-K (Exhibit 4.1) |
11/17/2016 |
001-37686 |
|
|
|
|
|
|
|
|
.2 |
Amendment No. 1 to Registration Rights Agreement, dated December 1, 2020, between the Registrant and the Investors |
|
8-K (Exhibit 10.1) |
12/2/2020 |
001-37686 |
|
|
|
|
|
|
|
|
.3 |
Amendment No. 2 to Registration Rights Agreement, dated May 3, 2023, between the Registrant and the Investors |
|
10-Q (Exhibit 10.3) |
5/4/2023 |
001-37686 |
Exhibit No. |
|
Exhibit Description |
Filed/ Furnished Herewith |
Incorporated by Reference
Herein from Form or Schedule |
Filing Date |
SEC File/ Reg. Number |
4.6 |
.1# |
Share Purchase Agreement, dated October 31, 2019, by and between the Registrant and Amgen Inc. |
|
10-K
(Exhibit 10.9) |
3/2/2020 |
001-37686 |
|
|
|
|
|
|
|
|
.2 |
Amendment No. 1 to Share Purchase Agreement, dated December 6, 2019, by and between the Registrant and Amgen Inc. |
|
10-K
(Exhibit 10.10) |
3/2/2020 |
001-37686 |
|
|
|
|
|
|
|
|
.3 |
Restated Amendment No. 2 to Share Purchase Agreement, dated September 24, 2020, by and between the Registrant and Amgen Inc. |
|
8-K
(Exhibit 10.1) |
9/24/2020 |
001-37686 |
|
|
|
|
|
|
|
|
.4 |
Amendment No. 3 to Share Purchase Agreement, dated January 30, 2023, by and between the Registrant and Amgen Inc. |
|
10-K
(Exhibit 10.4.4) |
2/27/2023 |
001-37686 |
|
|
|
|
|
|
|
5.1 |
|
Opinion of Mourant Ozannes (Cayman) LLP regarding the issue of ordinary shares being registered. |
X |
|
|
|
|
|
|
|
|
|
|
23.1 |
|
Consent of Ernst & Young LLP |
X |
|
|
|
|
|
|
|
|
|
|
23.2 |
|
Consent of Ernst & Young Hua Ming LLP |
X |
|
|
|
|
|
|
|
|
|
|
23.3 |
|
Consent of Mourant Ozannes (Cayman) LLP (included in Exhibit 5.1). |
X |
|
|
|
|
|
|
|
|
|
|
24.1 |
|
Power of Attorney (included on the signature page). |
X |
|
|
|
|
|
|
|
|
|
|
99.1† |
|
Third Amended and Restated 2016 Share Option and Incentive Plan |
|
8-K
(Exhibit 10.1) |
6/5/2024 |
001-37686 |
|
|
|
|
|
|
|
99.2† |
|
Fourth Amended and Restated 2018 Employee Share Purchase Plan |
|
8-K
(Exhibit 10.2) |
6/5/2024 |
001-37686 |
|
|
|
|
|
|
|
107 |
|
Filing Fee Table |
X |
|
|
|
| † | Indicates a management contract or any
compensatory plan, contract or arrangement. |
| | |
| # | Certain portions of the exhibit have been omitted by means of redacting a portion of the text and replacing
it with "[...***...]". BeiGene, Ltd. (the Registrant) has determined that the omitted information (i) is not material
and (ii) would be competitively harmful if publicly disclosed. |
SIGNATURES
Pursuant to the requirements of the Securities
Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for
filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly
authorized, in the Cayman Islands, on June 5, 2024.
|
BEIGENE, LTD. |
|
|
|
|
By: |
/s/ JOHN V. OYLER |
|
Name: |
John V. Oyler |
|
Title: |
Chief Executive Officer and Chairman |
POWER OF ATTORNEY
We, the undersigned directors, officers and/or
authorized representative of BeiGene, Ltd., hereby severally constitute and appoint John V. Oyler, Julia Wang and Chan Lee, and each
of them singly, our true and lawful attorneys, with full power to any of them, and to each of them singly, to sign for us and in our names
in the capacities indicated below the registration statement on Form S-8 filed herewith, and any and all pre-effective and post-effective
amendments to said registration statement, under the Securities Act of 1933, as amended, in connection with the registration under the
Securities Act of 1933, as amended, of equity securities of BeiGene, Ltd., and to file or cause to be filed the same, with all exhibits
thereto and other documents in connection therewith, with the U.S. Securities and Exchange Commission, granting unto said attorneys, and
each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection
therewith, as fully to all intents and purposes as each of them might or could do in person, and hereby ratifying and confirming all that
said attorneys, and each of them, or their substitute or substitutes, shall do or cause to be done by virtue of this Power of Attorney.
Pursuant to the requirements of the Securities
Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.
Signature |
|
Title |
|
Date |
|
|
|
|
|
/s/ JOHN V. OYLER |
|
Chief Executive Officer and Chairman |
|
June 5, 2024 |
John V. Oyler |
(Principal Executive Officer) |
|
|
|
|
|
|
/s/ JULIA WANG |
|
Chief Financial Officer |
|
June 5, 2024 |
Julia Wang |
(Principal Financial Officer) |
|
|
|
|
|
|
/s/ TITUS BALL |
|
Chief Accounting Officer |
|
June 5, 2024 |
Titus Ball |
(Principal Accounting Officer) |
|
|
|
|
|
|
/s/ OLIVIER BRANDICOURT |
|
Director |
|
June 5, 2024 |
Olivier Brandicourt |
|
|
|
|
|
|
|
|
|
/s/ MARGARET DUGAN |
|
Director |
|
June 5, 2024 |
Margaret Dugan |
|
|
|
|
|
|
|
|
|
/s/ DONALD W. GLAZER |
|
Director |
|
June 5, 2024 |
Donald W. Glazer |
|
|
|
|
|
|
|
/s/ MICHAEL GOLLER |
|
Director |
|
June 5, 2024 |
Michael Goller |
|
|
|
|
|
|
|
/s/ ANTHONY C. HOOPER |
|
Director |
|
June 5, 2024 |
Anthony C. Hooper |
|
|
|
|
|
|
|
|
|
/s/ RANJEEV KRISHANA |
|
Director |
|
June 5, 2024 |
Ranjeev Krishana |
|
|
|
|
|
|
|
/s/ ALESSANDRO RIVA |
|
Director |
|
June 5, 2024 |
Alessandro Riva |
|
|
|
|
|
|
|
|
|
/s/ CORAZON (CORSEE) D. SANDERS |
|
Director |
|
June 5, 2024 |
Corazon (Corsee) D. Sanders |
|
|
|
|
|
|
|
/s/ XIAODONG WANG |
|
Director |
|
June 5, 2024 |
Xiaodong Wang |
|
|
|
|
|
|
|
/s/ QINGQING YI |
|
Director |
|
June 5, 2024 |
Qingqing Yi |
|
|
BeiGene USA, Inc. |
|
|
|
|
|
|
Authorized Representative in the United States |
|
June 5, 2024 |
By: |
/s/ CHAN LEE |
|
|
|
|
Name: |
Chan Lee |
|
|
|
|
Title: |
Senior Vice President, General Counsel |
|
|
|
|
Exhibit 5.1
| Mourant Ozannes (Cayman) LLP
94 Solaris Avenue
Camana Bay
PO Box 1348
Grand Cayman KY1-1108
Cayman Islands
T +1 345 949 4123
F +1 345 949 4647
|
BeiGene, Ltd.
c/o Mourant Governance Services (Cayman) Limited
94 Solaris Avenue, Camana Bay
Grand Cayman KY1-1108
Cayman Islands
5 June 2024
Dear Sirs,
BeiGene, Ltd. (the Company)
We have acted as Cayman Islands legal advisers
to the Company and have examined the registration statement on Form S-8 (the Registration Statement), to be filed by the Company
with the Securities and Exchange Commission (the Commission) relating to the registration under the Securities Act of 1933, as
amended, of:
(a) | an additional 92,820,000 Ordinary Shares of par value US$0.0001 in the capital of the Company (the 2016
Equity Plan Shares) for issuance pursuant to the Company's Third Amended and Restated 2016 Share Option and Incentive Plan, approved
by the Company's shareholders on 5 June 2024 (the 2016 Equity Plan); and |
(b) | an additional 5,070,000 Ordinary Shares of par value US$0.0001 in the capital of the Company (together
with the 2016 Equity Plan Shares, the Shares) for issuance pursuant to the Company's Fourth Amended and Restated 2018 Employee
Share Purchase Plan, approved by the Company's shareholders on 5 June 2024 (together with the 2016 Equity Plan, the Plans
and each a Plan). |
As Cayman Islands counsel to the Company, we have
examined the corporate authorisations of the Company in connection with the establishment of each Plan, the registration of each Plan
with the Commission and the issue of the Shares pursuant to the Plans by the Company and have assumed that the Shares have been and will
be issued in accordance with the Plans and the resolutions authorising their issue. Furthermore, we have assumed that the resolutions
upon which we have relied were passed by the directors of the Company and/or the shareholders of the Company in the manner provided for
in the articles of association of the Company which were in full force and effect at the time that the authorisations were given and that
those authorisations have not been in any way amended, revoked or superseded and are in full force and effect.
It is our opinion that the Shares to be issued
by the Company have been duly and validly authorised, and when issued, sold and paid for in the manner described in the Plans in accordance
with the resolutions adopted by the board of directors of the Company (or any committee to whom the board of directors have delegated
their powers with respect to administration of the Plans) and when appropriate entries have been made in the register of members of the
Company, will be legally issued and credited as fully paid and non-assessable.
This opinion is subject to the qualification that
under the Companies Act (as amended) of the Cayman Islands (the Companies Act), the register of members of a Cayman Islands company
is by statute regarded as prima facie evidence of any matters which the Companies Act directs or authorises to be inserted therein.
A third party interest in the Shares in question would not appear. An entry in the register of members may yield to a court order for
rectification (for example, in the event of fraud or manifest error).
In this opinion the phrase non-assessable
means, with respect to Shares in the Company, that a member shall not, solely by virtue of its status as a member, be liable for additional
assessments or calls on the Shares by the Company or its creditors (except in exceptional circumstances and subject to the Company's articles
of association, such as involving fraud, the establishment of an agency relationship or an illegal or improper purpose or other circumstances
in which a court may be prepared to pierce or lift the corporate veil).
Mourant Ozannes (Cayman) LLP
is registered as a limited liability partnership in the Cayman Islands with registration number 601078
BVI | CAYMAN ISLANDS | GUERNSEY | HONG KONG | JERSEY | LONDON | mourant.com |
We consent to the use of this opinion as an exhibit
to the Registration Statement and further consent to all references to us in the Registration Statement and any amendments thereto. In
giving such consent, we do not consider that we are "experts" within the meaning of such term as used in the Securities
Act of 1933, as amended, or the rules and regulations of the Securities and Exchange Commission issued thereunder, with respect to
any part of the Registration Statement, including this opinion as an exhibit or otherwise.
Yours faithfully
/s/ Mourant Ozannes (Cayman) LLP
Mourant Ozannes (Cayman) LLP
Exhibit 23.1
Consent of Independent Registered Public Accounting
Firm
We consent to the incorporation by reference in the Registration Statement
(Form S-8) pertaining to the BeiGene, Ltd. Third Amended and Restated 2016 Share Option and Incentive Plan and the Fourth Amended
and Restated 2018 Employee Share Purchase Plan of our reports dated February 26, 2024, with respect to the consolidated financial
statements of BeiGene, Ltd., and the effectiveness of internal control over financial reporting of BeiGene, Ltd. included in
its Annual Report (Form 10-K) for the year ended December 31, 2023, filed with the Securities and Exchange Commission.
/s/ Ernst & Young LLP
Boston, Massachusetts
June 5, 2024
Exhibit 23.2
Consent of Independent Registered Public Accounting
Firm
We consent to the incorporation by reference in
the Registration Statement (Form S-8) pertaining to the Third Amended and Restated 2016 Share Option and Incentive Plan and the Fourth
Amended and Restated 2018 Employee Share Purchase Plan of BeiGene, Ltd. of our report dated February 28, 2022 (except for the effects
on the consolidated financial statements of the correction of an error, as to which the date is February 27, 2023), with respect to the
consolidated financial statements of BeiGene, Ltd. for the year ended December 31, 2021, included in its Annual Report (Form 10-K) for
the year ended December 31, 2023 filed with the Securities and Exchange Commission.
/s/ Ernst & Young Hua Ming LLP
Beijing, People’s Republic of China
June 5, 2024
Exhibit 107
CALCULATION
OF FILING FEE TABLE
Form S-8
(Form Type)
BEIGENE, LTD.
(Exact name
of Registrant as Specified in its Charter)
Table 1: Newly Registered Securities
|
|
|
|
Security
Type |
Security Class Title |
Fee
Calculation
Rule |
Amount
Registered(2) |
Proposed
Maximum
Offering Price Per
Unit |
Maximum
Aggregate
Offering Price |
Fee Rate |
Amount of
Registration
Fee |
Equity |
Ordinary Shares, par value $0.0001 per share(1) |
Other |
92,820,000(3) |
$11.62(5) |
$1,078,568,400 |
0.00014760 |
$159,196.70 |
Equity |
Ordinary Shares, par value $0.0001 per share(1) |
Other |
5,070,000(4) |
$9.87(6) |
$50,040,900 |
0.00014760 |
$7,386.04 |
Total Offering Amounts |
|
$1,128,609,300 |
|
$166,582.74 |
Total Fee Offsets |
|
|
|
— |
Net Fee Due |
|
|
|
$166,582.74 |
|
|
|
|
|
|
|
|
(1) |
These shares may be represented by the Registrant’s American Depositary Shares (“ADSs”). Each ADS represents 13 Ordinary
Shares. ADSs issuable upon deposit of the Ordinary Shares registered hereby were registered pursuant to a separate Registration Statement
on Form F-6 (File No. 333-209044). |
|
(2) |
Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration
Statement shall also cover any additional Ordinary Shares of the Registrant which become issuable in respect of the securities identified
in the above table by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without the receipt
of consideration that increases the number of the Registrant’s outstanding Ordinary Shares. |
|
(3) |
Represents an increase of 92,820,000 Ordinary Shares under the Registrant’s Third Amended and Restated 2016 Share Option and Incentive
Plan, effective June 5, 2024 (the “2016 Plan”). Ordinary Shares available for issuance under the 2016 Plan were previously
registered on Registration Statements on Form S-8 filed with the Securities and Exchange Commission on February 5, 2016 (File
No. 333-209410), March 22, 2017 (File No. 333-216885), February 28, 2018 (File No. 333-223319), December 13,
2018 (File No. 333-228786), August 6, 2020 (File No. 333-241697), and August 8, 2022 (File No. 333-266639). |
|
(4) |
Represents an increase of 5,070,000 Ordinary Shares under the Registrant’s Fourth Amended and Restated 2018 Employee Share Purchase
Plan, effective June 5, 2024 (the “2018 ESPP”). Ordinary Shares available for issuance under the 2018 ESPP were previously
registered on Registration Statements on Form S-8 filed with the Securities and Exchange Commission on June 8, 2018 (File No. 333-225543)
and December 13, 2018 (File No. 333-228786). |
|
(5) |
Estimated in accordance with Rule 457(c) and (h) under the Securities Act, solely for the purpose of calculating the registration
fee on basis of $151.00, the average of the high ($155.05) and low ($146.94) prices of the Registrant’s ADSs, as quoted on the
Nasdaq Global Select Market on May 31, 2024, divided by 13, the then Ordinary Share-to-ADS ratio. |
|
(6) |
Estimated in accordance with Rule 457(c) and (h) under the Securities Act, solely for the purpose of calculating the registration
fee on basis of $128.35, which is 85% of the average of the high ($155.05) and low ($146.94) prices of the Registrant’s ADSs, as
quoted on the Nasdaq Global Select Market on May 31, 2024, divided by 13, the then Ordinary Share-to-ADS ratio. Pursuant to the
2018 ESPP, shares are purchased at a price equal to 85% of the fair market value of our ordinary shares on either the first business
day of the offering period or the last business day of the offering period, whichever is lower. |
BeiGene (NASDAQ:BGNE)
Historical Stock Chart
From Aug 2024 to Sep 2024
BeiGene (NASDAQ:BGNE)
Historical Stock Chart
From Sep 2023 to Sep 2024